PRICING SHEET TEMPLATE - Attachment 1.xlsx
XLSX spreadsheet 26 KB Posted
- Solicitation number
- 15DDHQ24R00000025
About this file
This document is a Pricing Sheet Template for Attachment 1 related to a federal contract opportunity. The contract is for the Evaluation of Abuse Potential of Synthetic Opioids and Other Depressants, and Hallucinogenic Substances Using In Vivo Pharmacological Studies, issued by the Drug Enforcement Administration (DEA). The template provides detailed pricing for various assays and tests to be conducted over five ordering periods, including Locomotor Activity Assay, Antagonist Studies, Drug Discrimination, and Drug Costs. The total estimated price per ordering period is $85,000, with 15 test drugs and 2 reference drugs to be evaluated each period. The related federal contract opportunity provides additional details on the scope of work, which includes investigating the abuse potential of synthetic opioids, depressants, and hallucinogenic substances using in vivo pharmacological studies. Contractors will be required to provide DEA with investigational study results and methodology descriptions.
View the file
Other files
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Summary
| PERIOD | Total Cost Per Ordering Period |
| ORDERING PERIOD 1 | |
| ORDERING PERIOD 2 | |
| ORDERING PERIOD 3 | |
| ORDERING PERIOD 4 | |
| ORDERING PERIOD 5 | |
| Total Cost |
ORDERING PERIOD 1
| PRICING SHEET TEMPLATE: ATTACHMENT 1 | |
| Title: | Evaluation of Abuse Potential of Synthetic Opioids and Other Depressants Using In Vivo Pharmacological Studies |
| Agency: | Drug Enforcement Administration | ||||
| ORDERING PERIOD 1 | |||||
| CLIN Line Item | Assay | Quantity | Unit | Unit Price | Estimated Total Price |
| 1 | Locomotor Activity Assay Cost | 17 | |||
| LOT | |||||
| 2 | Locomotor Activity Assay Incidental Cost | 17 |
| LOT | |||
| 3 | Antagonist Studies Assay Cost | 17 | |
| LOT | |||
| 4 | Antagonist Incidental Cost | 17 | |
| LOT | |||
| 5 | Drug Discrimination for initial training | 17 |
| LOT | |||
| 6 | Drug Discrimination for initial training Incidental Cost | 17 |
| LOT | |||
| 7 | Drug Discrimination (monthly maintenance of training drug) Assay Cost | 17 |
| LOT | |||
| 8 | Drug Discrimination (monthly maintenance of training drug) Incidental Cost | 17 |
| LOT | ||||||
| 9 | Drug Discrimination of test drug Assay Cost | 17 | LOT | |||
| 10 | Drug Discrimination of test drug Incidental Cost | 17 | LOT | |||
| 11 | Drug Cost Not to Exceed | 17 | LOT | $500.00 | $8,500.00 | |
| TOTAL COST ($) | ||||||
| ** NOTE: 15 Test Drugs + 2 Reference Drugs = 17 TOTAL DRUGS | ||||||
| 1 TOTAL |
ORDERING PERIOD 2
| PRICING SHEET TEMPLATE: ATTACHMENT 1 | |
| Title: | Evaluation of Abuse Potential of Hallucinogenic Substances Using In Vivo Pharmacological Studies |
| Agency: | Drug Enforcement Administration | ||||
| ORDERING PERIOD 2 | |||||
| CLIN Line Item | Assay | Quantity | Unit | Unit Price | Estimated Total Price |
| 1001 | Locomotor Activity Assay Cost | 17 | |||
| LOT | |||||
| 1002 | Locomotor Activity Assay Incidental Cost | 17 |
| LOT | |||
| 1003 | Antagonist Studies Assay Cost | 17 | |
| LOT | |||
| 1004 | Antagonist Incidental Cost | 17 | |
| LOT | |||
| 1005 | Drug Discrimination for initial training | 17 |
| LOT | |||
| 1006 | Drug Discrimination for initial training Incidental Cost | 17 |
| LOT | |||
| 1007 | Drug Discrimination (monthly maintenance of training drug) Assay Cost | 17 |
| LOT | |||
| 1008 | Drug Discrimination (monthly maintenance of training drug) Incidental Cost | 17 |
| LOT | |||||
| 1009 | Drug Discrimination of test drug Assay Cost | 17 | LOT | ||
| 1010 | Drug Discrimination of test drug Incidental Cost | 17 | LOT | ||
| 1011 | Drug Cost Not to Exceed | 17 | LOT | $500.00 | $8,500.00 |
| TOTAL COST ($) | |||||
| ** NOTE: 15 Test Drugs + 2 Reference Drugs = 17 TOTAL DRUGS |
ORDERING PERIOD 3
| PRICING SHEET TEMPLATE: ATTACHMENT 1 | |
| Title: | Evaluation of Abuse Potential of Hallucinogenic Substances Using In Vivo Pharmacological Studies |
| Agency: | Drug Enforcement Administration | ||||
| ORDERING PERIOD 3 | |||||
| CLIN Line Item | Assay | Quantity | Unit | Unit Price | Estimated Total Price |
| 2001 | Locomotor Activity Assay Cost | 17 | |||
| LOT | |||||
| 2002 | Locomotor Activity Assay Incidental Cost | 17 |
| LOT | |||
| 2003 | Antagonist Studies Assay Cost | 17 | |
| LOT | |||
| 2004 | Antagonist Incidental Cost | 17 | |
| LOT | |||
| 2005 | Drug Discrimination for initial training | 17 |
| LOT | |||
| 2006 | Drug Discrimination for initial training Incidental Cost | 17 |
| LOT | |||
| 2007 | Drug Discrimination (monthly maintenance of training drug) Assay Cost | 17 |
| LOT | |||
| 2008 | Drug Discrimination (monthly maintenance of training drug) Incidental Cost | 17 |
| LOT | |||||
| 2009 | Drug Discrimination of test drug Assay Cost | 17 | LOT | ||
| 2010 | Drug Discrimination of test drug Incidental Cost | 17 | LOT | ||
| 2011 | Drug Cost Not to Exceed | 17 | LOT | $500.00 | $8,500.00 |
| TOTAL COST ($) | |||||
| ** NOTE: 15 Test Drugs + 2 Reference Drugs = 17 TOTAL DRUGS |
ORDERING PERIOD 4
| PRICING SHEET TEMPLATE: ATTACHMENT 1 | |
| Title: | Evaluation of Abuse Potential of Hallucinogenic Substances Using In Vivo Pharmacological Studies |
| Agency: | Drug Enforcement Administration | ||||
| ORDERING PERIOD 4 | |||||
| CLIN Line Item | Assay | Quantity | Unit | Unit Price | Estimated Total Price |
| 3001 | Locomotor Activity Assay Cost | 17 | |||
| LOT | |||||
| 3002 | Locomotor Activity Assay Incidental Cost | 17 |
| LOT | |||
| 3003 | Antagonist Studies Assay Cost | 17 | |
| LOT | |||
| 3004 | Antagonist Incidental Cost | 17 | |
| LOT | |||
| 3005 | Drug Discrimination for initial training | 17 |
| LOT | |||
| 3006 | Drug Discrimination for initial training Incidental Cost | 17 |
| LOT | |||
| 3007 | Drug Discrimination (monthly maintenance of training drug) Assay Cost | 17 |
| LOT | |||
| 3008 | Drug Discrimination (monthly maintenance of training drug) Incidental Cost | 17 |
| LOT | |||||
| 3009 | Drug Discrimination of test drug Assay Cost | 17 | LOT | ||
| 3010 | Drug Discrimination of test drug Incidental Cost | 17 | LOT | ||
| 3011 | Drug Cost Not to Exceed | 17 | LOT | $500.00 | $8,500.00 |
| TOTAL COST ($) | |||||
| ** NOTE: 15 Test Drugs + 2 Reference Drugs = 17 TOTAL DRUGS |
ORDERING PERIOD 5
| PRICING SHEET TEMPLATE: ATTACHMENT 1 | |
| Title: | Evaluation of Abuse Potential of Hallucinogenic Substances Using In Vivo Pharmacological Studies |
| Agency: | Drug Enforcement Administration | ||||
| ORDERING PERIOD 5 | |||||
| CLIN Line Item | Assay | Quantity | Unit | Unit Price | Estimated Total Price |
| 4001 | Locomotor Activity Assay Cost | 17 | |||
| LOT | |||||
| 4002 | Locomotor Activity Assay Incidental Cost | 17 |
| LOT | |||
| 4003 | Antagonist Studies Assay Cost | 17 | |
| LOT | |||
| 4004 | Antagonist Incidental Cost | 17 | |
| LOT | |||
| 4005 | Drug Discrimination for initial training | 17 |
| LOT | |||
| 4006 | Drug Discrimination for initial training Incidental Cost | 17 |
| LOT | |||
| 4007 | Drug Discrimination (monthly maintenance of training drug) Assay Cost | 17 |
| LOT | |||
| 4008 | Drug Discrimination (monthly maintenance of training drug) Incidental Cost | 17 |
| LOT | |||||
| 4009 | Drug Discrimination of test drug Assay Cost | 17 | LOT | ||
| 4010 | Drug Discrimination of test drug Incidental Cost | 17 | LOT | ||
| 4011 | Drug Cost Not to Exceed | 17 | LOT | $500.00 | $8,500.00 |
| TOTAL COST ($) | |||||
| ** NOTE: 15 Test Drugs + 2 Reference Drugs = 17 TOTAL DRUGS |
File details come from the government source that posted it. Updated .